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Abstract
Background: In advanced stages, patients with Sézary Syndrome (SS) commonly report an ill-defined, severe and 
diffuse pruritus. Recently, it has been reported that Aprepitant, an oral neurokinin-1-receptor (NK1) antagonist, may 
have an important role in relief of refractory pruritus in patients with SS.
Material and methods: A prospective study which included four patients with SS, in whom pruritus is the main 
symptom, was performed. Our purpose was to assess efficacy of Aprepitant for treatment of refractory pruritus, 
secondary to SS. Patients were treated with Aprepitant 80 mg/d during 10 days and then the dosage was reduced 
to alternate days. The length of treatment ranged between 4 and 23 weeks. Improvement was assessed by the 
Dermatology Life Quality Index (DLQI) questionnaire, which ranges from 0 to 30, with high scores indicating worse 
outcome and by Visual Analogue Scale (VAS) which varies from 0 to 10, with higher scores meaning severe pruritus.
Results: Prior to treatment, subjects had severe pruritus with mean DLQI score of 21.5 (SD ± 2.4) and mean VAS 
score of 9.0 (SD ± 0.8). At the end of the treatment, a statistically significant reduction in both indexes (p<0.05) was 
evident. In all patients, an improvement of pruritus was rapidly observed after the first week of therapy. No side effects 
were reported.
Conclusion: The study confirms the effectiveness and safety of Aprepitant as an antipruritic agent in patients with 
refractory pruritus secondary to SS.
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Introduction
In advanced stages, patients with Sézary Syndrome (SS) commonly 
report an ill-defined, severe and diffuse pruritus that may turn into 
“burning pain”. This is responsible for significant morbidity and 
adversely affects patients’ quality of life.  It is known that pruritus, 
insomnia and depression impair significantly the quality of life and 
may even lead to suicide [1]. Multiple options are available for pruritus 
treatment, including topical and oral corticosteroids, anti-histamines, 
phototherapy, gabapentin, mirtazapine, amitriptyline or naltrexone, 
each with varying efficacy and side effects profiles. Recently, it has 
been reported that Aprepitant, an oral neurokinin-1-receptor (NK1) 
antagonist, may have an important role in relief of refractory pruritus 
in patients with SS [2,3]. 
Aprepitant was approved in 2003 to prevent both acute and delayed 
chemotherapy-induced nausea and vomiting [4]. The dominant ligand 
for NK1, substance P, has been found to be an important mediator in 
the induction and maintenance of pruritus [5]. Moreover, an increase 
of NK1 has been described on keratinocytes in patients with chronic 
pruritus. Thus, it seems reasonable for its use in the treatment of this 
important symptom.
Material and Methods
A prospective study which included four patients with SS, in whom 
pruritus was the main symptom, was performed. Our purpose was 
to assess efficacy of Aprepitant for treatment of refractory pruritus, 
secondary to SS. In all patients, pruritus could not be controlled 
with conventional treatments (Table 1). Patients were treated with 
Aprepitant 80 mg/d during 10 days and then the dosage was reduced to 
alternate days. The length of treatment ranged between 4 and 23 weeks. 
Improvement was assessed by the Dermatology Life Quality Index 
(DLQI) questionnaire, which ranges from 0 to 30, with high scores 
indicating worse outcome and by Visual Analogue Scale (VAS) which 
varies from 0 to 10, with higher scores meaning severe pruritus. When 
Aprepitant was introduced, the patients were not on other drugs. All 
patients have signed an informed consent. Statistically, T test was used 
to compare data.
Results
Three patients were women (75%). The mean age was 68 years. 
The time between the diagnosis of SS and the initiation of Aprepitant 
ranged from 5 to 18 months. All patients have been treated with other 
antipruritic agents, which included topical and oral corticosteroids, 
antihistamines, antidepressants, thalidomide and phototherapy (Table 
1). 
Prior to treatment, subjects had severe pruritus with mean DLQI 
score of 21.5 (SD ± 2.4) and mean VAS score of 9.0 (SD ± 0.8). At 
the end of the treatment, a statistically significant reduction in both 
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and ideal period of time for the treatment of this condition in view of 
its elevated cost.
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indexes (p<0.05) was evident (Table 1). One patient (Table 1, patient 
1) showed a good initial response but by the 12th day of treatment a 
substantial worsening of pruritus was noted. Therefore, after 4 weeks 
of treatment the drug was discontinued. The treatment failure was 
probably related with disease progression, confirmed by an increase of 
blood Sézary cells (SC) quantified by flow cytometry. The 2nd patient 
(Table 1, patient 2) received Aprepitant over 4 weeks with an excellent 
response. By the 4th week of treatment, Aprepitant was stopped in 
the other two patients (Table 1, patient 3 and 4), because they have 
achieved pruritus control. However, after the discontinuation, relapse 
of pruritus was observed. In these patients, after two weeks without 
treatment, Aprepitant was reintroduced with the same good response. 
In all patients, an improvement of pruritus was rapidly observed after 
the first week of therapy. No side effects were reported.
Conclusion
The study confirms the effectiveness and safety of Aprepitant as an 
antipruritic agent in patients with refractory pruritus secondary to SS. 
However, it would be still important to determine the optimal dosage 
Patients
Gender/Age/
Clinical outcome
Diagnosis 
of SS
Initiation and length of 
treatment with Aprepitant
Previous antipruritic 
therapy
Previous
therapy for SS
DLQI and VAS scores
before and after treatment with Aprepitant
Patient 1 † F/68
Initial good  
response
11/2010 11/03/11
4 weeks
TCS
Antihistamines
Antidepressant
Thalidomide
PUVA
Alemtuzumab
Before treatment:
DLQI: 23
VAS: 10
After treatment:
DLQI: 21
VAS: 8
Patient 2 M/65
Response
01/2010 10/02/2011
4 weeks
TCS
Antihistamines
Antidepressant
CVP
Alemtuzumab
Before treatment:
DLQI: 18
VAS: 9
After treatment:
DLQI: 3
VAS: 0
Patient 3 F/70
Response
07/2009 05/11/2010
‡ 21 weeks
TCS
Antihistamines
PUVA
Bexarotene
INF-α
CHOP
Alemtuzumab
Before treatment:
DLQI: 22
VAS: 9
After treatment:
DLQI: 4
VAS: 1
Patient 4 F/67
Response
04/2009 20/10/20
‡ 23 weeks
TCS
Antihistamines
Antidepressant
Bexarotene
INF-α
CHOP
Before treatment:
DLQI: 23
VAS: 8
After treatment:
DLQI: 4
VAS: 1
†This patient showed a good initial response, but by the 12th day he stopped responding to Aprepitant
‡The treatment was interrupted for two weeks
Abbreviations: F: Female; M: Male; TCS: Topical Corticosteroids; PUVA: Phototherapy UVA; CVP: Cyclophosphamide, Vincristine, and Prednisone; INF-α: Interferon α; 
CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Table 1: Representative table of patients treated with Aprepitant.
